A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Antivirals; Ledipasvir; Peginterferon alfa-2a; Ribavirin; Sofosbuvir; Tegobuvir; Vedroprevir
Indications Hepatitis C
Focus Therapeutic Use

31 Aug 2018 Biomarkers information updated
07 Mar 2013 Planned number of patients changed from 740 to 800 as reported by ClinicalTrials.gov.
07 Mar 2013 Planned end date changed from 1 Sep 2016 to 1 Sep 2019 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com